laminin 21

Insights from pediatric neurologist Carsten Bönnemann

posted on July 1, 2013 - 9:23am
Update (March 24, 2015): A phase 1 trial of omigapil in children and adolescents 5-16 years old who have merosin-deficient congenital muscular dystrophy and meet other study criteria is open in Bethesda, Md. See Assessment of Safety and Tolerability of Omigapil (CALLISTO), or enter NCT01805024 in the search box at ClinicalTrials.gov.

New content is being added every day. Please check back again.